Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
Status:
Terminated
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving chemotherapy, such as cyclophosphamide and fludarabine, and total-body
irradiation before a donor natural killer cell infusion helps stop the growth of tumor cells.
It also helps stop the patient's immune system from rejecting the donor's natural killer
cells. Aldesleukin may stimulate the natural killer cells to kill ovarian, fallopian tube, or
primary peritoneal cancer cells. Treating the donor natural killer cells with aldesleukin may
help the natural killer cells kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving laboratory-treated donor natural
killer cells together with aldesleukin works when given after cyclophosphamide, fludarabine,
and total-body irradiation in treating patients with recurrent and/or metastatic ovarian,
fallopian tube, or primary peritoneal cancer.